Pancreatic cancer is one of the most challenging malignancies in oncology. It is the third leading cause of cancer death in the United States, with approximately 64,000 new cases diagnosed each year. The overall five-year survival rate remains approximately 12%, though outcomes vary significantly based on stage at diagnosis and the type of pancreatic tumor.
The low survival rate is primarily driven by late diagnosis — roughly 80% of patients present with locally advanced or metastatic disease because early-stage pancreatic cancer rarely causes symptoms. However, advances in multimodal therapy, including more effective chemotherapy regimens and improved surgical techniques, have gradually improved outcomes for patients who are candidates for treatment.
Types of Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma accounts for approximately 90% of all pancreatic cancers. It arises from the exocrine cells lining the pancreatic ducts and is the type most people refer to when discussing pancreatic cancer. PDAC is characterized by a dense stromal (desmoplastic) reaction around the tumor, which limits drug penetration and contributes to chemotherapy resistance.
The majority of PDACs (60–70%) arise in the head of the pancreas, which can cause jaundice by obstructing the common bile duct — sometimes leading to earlier diagnosis compared to tumors in the body or tail.
Pancreatic Neuroendocrine Tumors (PNETs)
Pancreatic neuroendocrine tumors arise from the islet cells of the pancreas and account for approximately 5–7% of pancreatic cancers. PNETs have a substantially better prognosis than adenocarcinoma, with 5-year survival rates of approximately 50–60% overall and exceeding 90% for localized, well-differentiated tumors.
PNETs are classified as functional (hormone-secreting) or non-functional:
- Insulinomas — Secrete insulin, causing hypoglycemia. The most common functional PNET. Over 90% are benign.
- Gastrinomas — Secrete gastrin, causing Zollinger-Ellison syndrome (peptic ulcers, diarrhea). Often associated with MEN1 syndrome.
- Glucagonomas — Secrete glucagon, causing diabetes, skin rash (necrolytic migratory erythema), and weight loss.
- VIPomas — Secrete vasoactive intestinal peptide, causing profuse watery diarrhea.
- Non-functional PNETs — The most common type. Do not produce hormonal symptoms and are often diagnosed later due to mass effect or incidental imaging findings.
Risk Factors
- Smoking — The strongest modifiable risk factor. Smokers face a 2–3 fold increased risk. Responsible for an estimated 20–25% of cases.
- Chronic pancreatitis — Long-standing inflammation increases risk, particularly hereditary pancreatitis (PRSS1, SPINK1 mutations), which carries a lifetime risk of approximately 40%.
- Diabetes mellitus — Long-standing type 2 diabetes modestly increases risk. New-onset diabetes after age 50 may be an early sign of pancreatic cancer.
- Obesity — BMI ≥30 increases risk by approximately 20%.
- Family history and genetic syndromes — Approximately 10% of pancreatic cancers have a hereditary component. Associated syndromes include BRCA2 mutations (3–10 fold increased risk), PALB2, ATM, Lynch syndrome (MLH1, MSH2), familial atypical multiple mole melanoma (CDKN2A/p16), and Peutz-Jeghers syndrome (STK11).
- Age — Most cases are diagnosed after age 65. Median age at diagnosis is 70.
Diagnosis and Staging
Diagnostic Workup
- CT scan (pancreatic protocol) — The primary imaging modality. A triple-phase CT with thin slices provides detailed assessment of tumor size, vascular involvement, and metastatic disease. This determines resectability.
- Endoscopic ultrasound (EUS) — Provides high-resolution imaging and allows fine-needle aspiration (FNA) biopsy for tissue diagnosis.
- MRI/MRCP — Useful for characterizing liver lesions and evaluating the biliary and pancreatic ducts.
- CA 19-9 — The most commonly used tumor marker for pancreatic adenocarcinoma. Elevated (>37 U/mL) in approximately 80% of patients with PDAC. Useful for monitoring treatment response and detecting recurrence, but not specific enough for screening (also elevated in biliary obstruction, pancreatitis, and other GI cancers). Approximately 5–10% of the population are Lewis antigen-negative and will not produce CA 19-9 regardless of cancer status.
- Staging laparoscopy — Sometimes performed before planned surgery to identify peritoneal metastases not visible on imaging (present in 10–20% of patients thought to have resectable disease).
Resectability Classification
| Category | Definition | Treatment Approach |
|---|---|---|
| Resectable | No arterial or venous involvement; clear fat planes around major vessels | Upfront surgery followed by adjuvant chemotherapy |
| Borderline resectable | Limited venous involvement (SMV/portal vein) or arterial abutment ≤180 degrees | Neoadjuvant chemotherapy ± radiation, then reassess for surgery |
| Locally advanced | Extensive arterial encasement (>180 degrees of SMA, celiac axis) or unreconstructable venous involvement | Chemotherapy ± radiation; surgery only if significant response |
| Metastatic | Distant organ involvement (liver, lung, peritoneum) | Systemic chemotherapy; palliative care |
Surgical Treatment
The Whipple Procedure (Pancreaticoduodenectomy)
The Whipple procedure is the standard operation for tumors in the head of the pancreas. It is one of the most complex operations in general surgery, involving removal of the head of the pancreas, the duodenum, a portion of the stomach (classic Whipple) or pylorus preservation (pylorus-preserving Whipple), the gallbladder, and the common bile duct. Three anastomoses are then created to restore digestive continuity.
Operative mortality has decreased dramatically at high-volume centers (defined as ≥20 Whipple procedures per year), with current perioperative mortality rates of 1–3% compared to 15–20% historically at low-volume hospitals. This volume-outcome relationship makes center selection one of the most important decisions in pancreatic cancer treatment.
Distal Pancreatectomy
For tumors in the body or tail of the pancreas, a distal pancreatectomy is performed, typically including splenectomy. This operation is technically less complex than the Whipple procedure, and minimally invasive (laparoscopic or robotic) approaches are increasingly standard.
Total Pancreatectomy
Rarely performed, total pancreatectomy removes the entire pancreas and results in permanent insulin-dependent diabetes and exocrine insufficiency requiring lifelong pancreatic enzyme replacement. It is considered when the tumor involves the entire gland or when a positive surgical margin cannot be avoided with a less extensive resection.
Chemotherapy
Adjuvant Chemotherapy (After Surgery)
Adjuvant chemotherapy is standard after surgical resection and has been shown to significantly improve survival:
- Modified FOLFIRINOX — A combination of 5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin. The PRODIGE 24 trial demonstrated median overall survival of 54.4 months with modified FOLFIRINOX versus 35 months with gemcitabine alone. This is the preferred regimen for fit patients.
- Gemcitabine plus capecitabine — The ESPAC-4 trial showed improved OS (28.0 vs 25.5 months) compared to gemcitabine alone, with a manageable side effect profile. A good option for patients who cannot tolerate FOLFIRINOX.
- Gemcitabine monotherapy — The historical standard. Still used for patients unable to tolerate combination regimens.
First-Line Chemotherapy for Advanced Disease
- FOLFIRINOX or modified FOLFIRINOX — The ACCORD 11 trial established FOLFIRINOX as superior to gemcitabine alone for metastatic disease, with median OS of 11.1 versus 6.8 months. However, this regimen is more toxic (neutropenia, diarrhea, neuropathy) and is typically reserved for patients with good performance status (ECOG 0–1).
- Gemcitabine plus nab-paclitaxel (Abraxane) — The MPACT trial showed improved OS (8.5 vs 6.7 months) compared to gemcitabine alone, with a more tolerable side effect profile than FOLFIRINOX. The preferred option for patients who cannot tolerate FOLFIRINOX.
- NALIRIFOX — A newer regimen combining nano-liposomal irinotecan, 5-FU, leucovorin, and oxaliplatin. The NAPOLI-3 trial demonstrated improved OS versus gemcitabine/nab-paclitaxel (11.1 vs 9.2 months).
Targeted and Precision Therapy
- Olaparib (Lynparza) — A PARP inhibitor approved as maintenance therapy for patients with germline BRCA1/2-mutated metastatic pancreatic cancer that has not progressed on first-line platinum-based chemotherapy (POLO trial).
- Pembrolizumab (Keytruda) — Approved for MSI-high or dMMR tumors (approximately 1–2% of pancreatic cancers).
- Entrectinib or larotrectinib — For rare NTRK fusion-positive pancreatic cancers.
Radiation Therapy
The role of radiation in pancreatic cancer remains debated. Current applications include:
- Neoadjuvant chemoradiation — Sometimes used for borderline resectable disease, though the benefit over chemotherapy alone is uncertain.
- Adjuvant chemoradiation — More commonly used in the United States than in Europe. May benefit patients with positive surgical margins (R1 resection).
- Stereotactic body radiation therapy (SBRT) — An emerging approach delivering high-dose focused radiation in fewer sessions. Under investigation for locally advanced disease.
- Palliative radiation — Used for pain control, particularly for tumors causing back pain due to celiac plexus invasion.
Palliative Care
Given that the majority of pancreatic cancer patients present with advanced disease, palliative care is a critical component of treatment from the time of diagnosis. The ASCO guidelines recommend early integration of palliative care alongside disease-directed therapy.
- Biliary stenting — Endoscopic placement of a metal stent to relieve jaundice caused by bile duct obstruction. Preferred over surgical bypass when possible.
- Celiac plexus neurolysis — Injection of alcohol or other agents into the celiac plexus to block abdominal pain signals. Performed endoscopically (EUS-guided) or percutaneously. Effective in 70–80% of patients.
- Pancreatic enzyme replacement — Essential for patients with exocrine insufficiency (maldigestion, steatorrhea) caused by pancreatic duct obstruction or surgical resection.
- Nutritional support — Weight loss and cachexia are common. Dietary counseling, enzyme supplementation, and sometimes parenteral nutrition are important supportive measures.
- Gastric outlet obstruction management — Duodenal stenting or surgical gastrojejunostomy for patients with gastric outlet obstruction.
Clinical Trials and Emerging Research
Active areas of research in pancreatic cancer include KRAS-targeted therapies (KRAS G12C and G12D inhibitors), novel immunotherapy combinations, stromal-modifying agents, and therapeutic cancer vaccines. Given the limited treatment options, clinical trial participation is strongly encouraged at every stage of disease.